BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

IIT-D startup Sanfe develops glycoclear technology to revolutionise skin healthcare

09 February 2024 | News

Online femcare brand Sanfe is set to revolutionise the beauty and wellness sector



India’s existing body care market is poised towards fragrance or moisturisation-led products which are proven to be less effective on a vast range of complex body care issues of Indian women. After witnessing the lack of confidence in their female colleagues at a farewell party due to tanned skin, dark underarms, strawberry skin etc., Indian Institute of Technology (IIT) Delhi startup Sanfe founders Archit Agarwal and Harry Sehrawat decided to address this issue.

After months of rigorous research, these entrepreneurs developed the revolutionary glycoclear technology. This path-breaking skincare innovation transcends traditional boundaries, setting a new standard for feminine care and redefining the beauty narrative. In a groundbreaking stride towards empowering women and transforming the beauty market, Sanfe has launched this revolutionary glycoclear technology with one of the largest body care range.

At the core of this transformative technology lies the Glycoclear Complex, an intricate blend of AHAs (alpha-hydroxy acids), and BHAs (beta-hydroxy acids). It is a breakthrough innovation, which is proven for maintaining low pH, exfoliating the skin’s top layer from its very first use, accelerated penetration of actives, making it 3X quick in action and providing instant nourishment to skin making it smoother than ever.

Beyond its transformative impact, the glycoclear technology has been granted a trademark, solidifying its position as a pioneer in skincare innovation. As Sanfe propels into a new era of skincare, the glycoclear technology range encompasses 18 products, dermatologist-approved, and subjected to skin safety tests.

Sanfe's dedication to innovation is underscored by its financial commitment, with an audited turnover of Rs 47.5 crore for FY 2022-23, a significant increase from Rs 25.5 crore in FY 2021-22. The company allocates 5% of its turnover to research and innovation, aiming for a colossal target of achieving Rs 500 crore in the next 3 years, representing a remarkable 500% growth in 2-3 years. Through various funding rounds, this young brand has managed to raise $3.93 million.